<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587416</url>
  </required_header>
  <id_info>
    <org_study_id>A4141002</org_study_id>
    <nct_id>NCT02587416</nct_id>
  </id_info>
  <brief_title>Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers</brief_title>
  <official_title>A Study of the Effect of Oral, Multiple‐Dose 300 mg and 900 mg Gemcabene (CI‐1027) Administration on the Steady‐State Pharmacokinetics of Atorvastatin 80 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gemphire Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gemphire Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of gemcabene on the pharmacokinetics of
      atorvastatin 80 mg
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Days 5, 16 and 27</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Days 5, 16, and 27</time_frame>
    <description>Area Under the Curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>27 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory - hematology, chemistry, urinalysis</measure>
    <time_frame>27 days</time_frame>
    <description>Clinical Laboratory Abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>27 days</time_frame>
    <description>Clinically Significant Changes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hypercholesteremia</condition>
  <arm_group>
    <arm_group_label>Gemcabene 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 900 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 80 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 300 mg</intervention_name>
    <description>1x300 mg gemcabene tablets orally once daily (QD) for 11 days</description>
    <arm_group_label>Gemcabene 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 900 mg</intervention_name>
    <description>3x300 mg Gemcabene tablets orally once daily (QD) for 11 days</description>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>2x40 mg Atorvastatin tablets orally once daily (QD)</description>
    <arm_group_label>Gemcabene 300 mg</arm_group_label>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females

          -  18‐65 years of age

          -  Good health as determined by medical history, physical examination, vital signs, ECG,
             and clinical laboratory measurements;

          -  Body weight 45 kg or greater, with a body mass index (BMI) ≤ 35 kg/m² (weight
             [kg]/height[meters]²)

        Exclusion Criteria:

          -  If female, of childbearing potential or lactation

          -  History of significant adverse reaction to any lipid‐lowering agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Lipid Regulator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

